全文获取类型
收费全文 | 1401篇 |
免费 | 56篇 |
国内免费 | 1篇 |
专业分类
耳鼻咽喉 | 13篇 |
儿科学 | 104篇 |
妇产科学 | 53篇 |
基础医学 | 235篇 |
口腔科学 | 73篇 |
临床医学 | 111篇 |
内科学 | 273篇 |
皮肤病学 | 26篇 |
神经病学 | 69篇 |
特种医学 | 21篇 |
外科学 | 167篇 |
综合类 | 5篇 |
预防医学 | 127篇 |
眼科学 | 12篇 |
药学 | 64篇 |
中国医学 | 1篇 |
肿瘤学 | 104篇 |
出版年
2022年 | 5篇 |
2021年 | 11篇 |
2020年 | 7篇 |
2019年 | 16篇 |
2018年 | 17篇 |
2017年 | 16篇 |
2016年 | 14篇 |
2015年 | 18篇 |
2014年 | 25篇 |
2013年 | 93篇 |
2012年 | 88篇 |
2011年 | 90篇 |
2010年 | 40篇 |
2009年 | 44篇 |
2008年 | 116篇 |
2007年 | 105篇 |
2006年 | 101篇 |
2005年 | 89篇 |
2004年 | 86篇 |
2003年 | 100篇 |
2002年 | 99篇 |
2001年 | 16篇 |
2000年 | 3篇 |
1999年 | 15篇 |
1998年 | 21篇 |
1997年 | 18篇 |
1996年 | 13篇 |
1995年 | 20篇 |
1994年 | 15篇 |
1993年 | 9篇 |
1992年 | 13篇 |
1991年 | 5篇 |
1990年 | 5篇 |
1989年 | 10篇 |
1988年 | 8篇 |
1987年 | 4篇 |
1986年 | 3篇 |
1985年 | 5篇 |
1984年 | 10篇 |
1983年 | 6篇 |
1982年 | 16篇 |
1981年 | 7篇 |
1980年 | 8篇 |
1979年 | 7篇 |
1978年 | 6篇 |
1977年 | 6篇 |
1976年 | 5篇 |
1975年 | 3篇 |
1972年 | 4篇 |
1967年 | 4篇 |
排序方式: 共有1458条查询结果,搜索用时 15 毫秒
51.
Jorma Kokkonen Sami Tikkanen Tuomo J. Karttunen Erkki Savilahti 《Pediatric allergy and immunology》2002,13(2):129-136
In previous studies, we have reported endoscopic and histological alterations locally on the gastrointestinal (GI) tract associated with a gastrointestinal type of cow's milk allergy. In this study, we sought to further characterize endoscopic, and immunological findings in these children. We also hypothesized that the same type of immune responses might also be found in children with unexplained and recurrent abdominal pains. We did a gastroduodenoscopy for persistent GI symptoms, examined the mucosal histology of the small intestine and measured the antibodies to whole cow's milk and its fractions with an enzyme‐linked immunosorbent assay (ELISA) in a consecutive series of 22 subjects with untreated and 14 with treated cow's milk allergy (CMA) and 44 with recurrent abdominal pains (RAP). The immunological findings of the study subjects were compared with 54 controls. Lymphonodular hyperplasia (LNH) of the duodenum was the main endoscopic finding in 11 subjects (50%) with untreated and 5 (36%) with treated CMA. It was also found in 6 of 44 subjects with RAP. Compared with the controls, the patients with CMA showed significantly higher levels of IgA class antibodies to whole milk (p = 0.003) and βLG (p < 0.0001). Of the IgG class antibodies to βLG (p = 0.032), BSA (p < 0.0001) and αCAS (p < 0.0001) were significantly higher. The patients with LNH of the duodenal bulb as the main endoscopic finding showed significantly higher values of IgG class antibodies to βLG (p = 0.01) and αCAS (p = 0.005). Interestingly, the patients examined for RAP showed a similar increment in the pattern of whole milk and specific milk protein antibodies as the CMA children. In conclusion this study showed that gastrointestinal CMA beyond infancy is significantly associated with high levels of IgG and IgA class antibodies to milk and its fractions. As high levels of these antibodies and LNH of the duodenal bulb were also found in subjects with RAP, the study further suggests that gastrointestinal CMA might be one major reason for RAP. 相似文献
52.
53.
Objective
Aurora-A is a potential oncogene and therapeutic target in ovarian carcinoma. It is involved in mitotic events and overexpression leads to centrosome amplification and chromosomal instability. The objective of this study was to evaluate the clinical significance of Aurora-A and DNA ploidy in serous ovarian carcinoma.Methods
Serous ovarian carcinomas were analysed for Aurora-A protein by immunohistochemistry (n = 592), Aurora-A copy number by CISH (n = 169), Aurora-A mRNA by real-time PCR (n = 158) and DNA ploidy by flowcytometry (n = 440).Results
Overexpression of Aurora-A was found in 27% of the tumors, cytoplasmic overexpression in 11% and nuclear in 17%. The cytoplasmic and nuclear overexpression were nearly mutually exclusive. Both cytoplasmic and nuclear overexpression were associated with shorter survival, high grade, high proliferation index and aberrant p53. Interestingly, only cytoplasmic expression was associated with aneuploidy and expression of phosphorylated Aurora-A. DNA ploidy was associated with poor patient outcome as well as aggressive clinicopathological parameters. In multivariate analysis, Aurora-A overexpression appeared as an independent prognostic factor for disease-free survival, together with grade, stage and ploidy.Conclusions
Aurora-A protein expression is strongly linked with poor patient outcome and aggressive disease characteristics, which makes Aurora-A a promising biomarker and a potential therapeutic target in ovarian carcinoma. Cytoplasmic and nuclear Aurora-A protein may have different functions. DNA aneuploidy is a strong predictor of poor prognosis in serous ovarian carcinoma. 相似文献54.
Estimation of genetic risk for type 1 diabetes 总被引:8,自引:0,他引:8
Ilonen J Sjöroos M Knip M Veijola R Simell O Akerblom HK Paschou P Bozas E Havarani B Malamitsi-Puchner A Thymelli J Vazeou A Bartsocas CS 《American journal of medical genetics》2002,115(1):30-36
The most important gene loci defining risk of type 1 diabetes mellitus (T1DM) are located within the HLA gene region. HLA-DQ molecules are of primary importance but HLA-DR gene products modify the risk conferred by HLA-DQ. The risk associated with an HLA genotype is defined by the particular combination of susceptible and protective alleles. The highest risk is associated with a combination of two different risk haplotypes (7% risk to develop T1DM in Finland) whereas protective genotypes covering 69% of population have a risk of less than 0.2%). The complicated analysis of HLA genotypes is simplified by strong linkage disequilibrium between HLA-DRB1, -DQA1 and -DQB1 loci. In many cases one can deduce the alleles of other loci based on determination of the alleles in one locus. Differences between various populations in the frequency of marker alleles and in the linkages between them has to be taken into account. We have developed PCR based typing methods that utilize blood spot samples, microtiter plate format and lanthanide labeled oligonucleotide probes to define HLA-DQ and -DR alleles relevant for T1DM risk. Typing is run stepwise so that after initial HLA-DQB1 typing only those samples will be further analyzed in which -DQA1 or -DRB1 typing is informative and expected to contribute to the risk estimation. This method has been used to screen more than 50,000 newborn infants in Finland over a time period of 6 years, and it has been able to identify most children who have developed T1D during the follow-up period. The efficiency of the procedure has also been tested in Finnish and Greek populations. 相似文献
55.
56.
Milla Valta Ahmad Mahfuz Gazali Tyyne Viisanen Emmi-Leena Ihantola Ilse Ekman Jorma Toppari Mikael Knip Riitta Veijola Jorma Ilonen Johanna Lempainen Tuure Kinnunen 《European journal of immunology》2020,50(4):581-588
Dysfunction of FOXP3-positive regulatory T cells (Tregs) likely plays a major role in the pathogenesis of multiple autoimmune diseases including type 1 diabetes (T1D). Whether genetic polymorphisms associated with the risk of autoimmune diseases affect Treg frequency or function is currently unclear. Here, we analysed the effect of T1D-associated major HLA class II haplotypes and seven single nucleotide polymorphisms in six non-HLA genes [INS (rs689), PTPN22 (rs2476601), IL2RA (rs12722495 and rs2104286), PTPN2 (rs45450798), CTLA4 (rs3087243), and ERBB3 (rs2292239)] on peripheral blood Treg frequencies. These were determined by flow cytometry in 65 subjects who had progressed to T1D, 86 islet autoantibody-positive at-risk subjects, and 215 islet autoantibody-negative healthy controls. The PTPN22 rs2476601 risk allele A was associated with an increase in total (p = 6 × 10−6) and naïve (p = 4 × 10−5) CD4+CD25+CD127lowFOXP3+ Treg frequencies. These findings were validated in a separate cohort comprising ten trios of healthy islet autoantibody-negative children carrying each of the three PTPN22 rs2476601 genotypes AA, AG, and GG (p = 0.005 for total and p = 0.03 for naïve Tregs, respectively). In conclusion, our analysis implicates the autoimmune PTPN22 rs2476601 risk allele A in controlling the frequency of Tregs in human peripheral blood. 相似文献
57.
Johannsson OT Staff S Vallon-Christersson J Kytöla S Gudjonsson T Rennstam K Hedenfalk IA Adeyinka A Kjellén E Wennerberg J Baldetorp B Petersen OW Olsson H Oredsson S Isola J Borg A 《Laboratory investigation; a journal of technical methods and pathology》2003,83(3):387-396
A human tumor xenograft (L56Br-X1) was established from a breast cancer axillary lymph node metastasis of a 53-year-old woman with a BRCA1 germ-line nonsense mutation (1806C>T; Q563X), and a cell line (L56Br-C1) was subsequently derived from the xenograft. The xenograft carries only the mutant BRCA1 allele and expresses mutant BRCA1 mRNA but no BRCA1 protein as determined by immunoprecipitation or Western blotting. The primary tumor, lymph node metastasis, and xenograft were hypodiploid by DNA flow cytometry, whereas the cell line displayed an aneuploidy apparently developed via polyploidization. Cytogenetic analysis, spectral karyotyping, and comparative genomic hybridization of the cell line revealed a highly complex karyotype with numerous unbalanced translocations. The xenograft and cell line had retained a somatic TP53 missense mutation (S215I) originating from the primary tumors, as well as a lack of immunohistochemically detectable expression of steroid hormone receptors, epidermal growth factor receptor, human epidermal growth factor receptor 2 (HER-2), and keratin 8. Global gene expression analysis by cDNA microarrays supported a correlation between the expression profiles of the primary tumor, lymph node metastasis, xenograft, and cell line. We conclude that L56Br-X1 and L56Br-C1 are useful model systems for studies of the pathogenesis and new therapeutic modalities of BRCA1-induced human breast cancer. 相似文献
58.
59.
Michael Bilous Mitch Dowsett Wedad Hanna Jorma Isola Annette Lebeau Aberlardo Moreno Frédérique Penault-Llorca Josef Rüschoff Gorana Tomasic Marc van de Vijver 《Modern pathology》2003,16(2):173-182
Knowledge of HER2 status is a prerequisite when considering a patient's eligibility for Herceptin (trastuzumab) therapy. Accurate assessment of HER2 status is essential to ensure that all patients who may benefit from Herceptin are correctly identified. There are several assays available to determine HER2 status: the most common in routine clinical practice are immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH). Various factors can affect the results achieved with these assays, including the assay antibody/probe, the methodology and the experience of personnel. Many countries have implemented national testing guidelines in an attempt to standardize testing procedures and make results more accurate. These guidelines vary in the level of detail and the number of recommendations. This review looks at areas of consensus between the different national testing guidelines and highlights where errors may arise during the testing procedure. The key point underlined by this review is that whatever method is used to test for HER2 status, the technology must be validated first, and there must be regular internal and external quality control and quality assurance procedures. 相似文献
60.
Yang Liu Mei Wang Jorma Tynjälä Yan Lv Jari Villberg Zhouyang Zhang Lasse Kannas 《BMC medical research methodology》2010,10(1):73